Medifast (NYSE:MED) Shares Pass Above Two Hundred Day Moving Average – Should You Sell?

Shares of Medifast Inc (NYSE:MED) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.16 and traded as high as $12.45. Medifast shares last traded at $12.2950, with a volume of 112,614 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MED shares. Stephens decreased their target price on Medifast from $15.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, February 19th. Wall Street Zen upgraded Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings downgraded Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $12.00.

Medifast Stock Down 1.6%

The firm’s 50 day simple moving average is $11.51 and its 200 day simple moving average is $11.16. The company has a market cap of $134.26 million, a price-to-earnings ratio of -6.60 and a beta of 0.62.

Medifast (NYSE:MED) last announced its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.36. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. The company had revenue of $76.04 million for the quarter, compared to analyst estimates of $69.20 million. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. Analysts anticipate that Medifast Inc will post -1.97 EPS for the current fiscal year.

Insider Activity at Medifast

In other news, Director Scott Schlackman purchased 2,500 shares of the company’s stock in a transaction on Monday, May 11th. The shares were bought at an average price of $12.53 per share, for a total transaction of $31,325.00. Following the completion of the purchase, the director owned 30,549 shares of the company’s stock, valued at $382,778.97. This trade represents a 8.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel R. Chard acquired 17,678 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were bought at an average price of $10.11 per share, for a total transaction of $178,724.58. Following the purchase, the chief executive officer directly owned 17,678 shares of the company’s stock, valued at approximately $178,724.58. This trade represents a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 22,678 shares of company stock worth $241,675 in the last 90 days. 3.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MED. Lido Advisors LLC acquired a new position in shares of Medifast during the third quarter valued at approximately $4,521,000. Steamboat Capital Partners LLC acquired a new position in shares of Medifast during the fourth quarter valued at approximately $2,952,000. Charles Schwab Investment Management Inc. increased its stake in shares of Medifast by 30.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock valued at $8,297,000 after acquiring an additional 181,618 shares during the period. Bank of America Corp DE increased its stake in shares of Medifast by 37.4% during the second quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock valued at $5,569,000 after acquiring an additional 107,854 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in shares of Medifast during the third quarter valued at approximately $867,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight?loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight?management solutions.